These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 18481487

  • 21. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
    Liepe K, Runge R, Kotzerke J.
    J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
    [Abstract] [Full Text] [Related]

  • 22. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Dec; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS.
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 30. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Liepe K, Kotzerke J.
    Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
    [Abstract] [Full Text] [Related]

  • 31. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
    Strigari L, Sciuto R, D'Andrea M, Pasqualoni R, Benassi M, Maini CL.
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1031-8. PubMed ID: 17237963
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH, Zonneberg BA, de Klerk JM, Quirijnen JM, van het Schip AD, van Dijk A, Blijham GH, van Rijk PP.
    J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
    [Abstract] [Full Text] [Related]

  • 37. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J, Vizd'a J, Cermáková E.
    Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
    [Abstract] [Full Text] [Related]

  • 38. Bench to bedside development of GMP grade Rhenium-188-HEDP, a radiopharmaceutical for targeted treatment of painful bone metastases.
    ter Heine R, Lange R, Breukels OB, Bloemendal HJ, Rummenie RG, Wakker AM, de Graaf H, Beekman FJ, van der Westerlaken MM, Malingré MM, Wielders JP, van den Berg L, Hendrikse NH, de Klerk JM.
    Int J Pharm; 2014 Apr 25; 465(1-2):317-24. PubMed ID: 24560635
    [Abstract] [Full Text] [Related]

  • 39. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
    Jong JM, Oprea-Lager DE, Hooft L, de Klerk JM, Bloemendal HJ, Verheul HM, Hoekstra OS, van den Eertwegh AJ.
    Eur Urol; 2016 Sep 25; 70(3):416-26. PubMed ID: 26391636
    [Abstract] [Full Text] [Related]

  • 40. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
    Orsini F, Guidoccio F, Mazzarri S, Mariani G.
    J Nucl Med; 2012 Aug 25; 53(8):1330-1; author reply 1332. PubMed ID: 22717979
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.